Emerging Trends in Cell Therapy for Immune Complications Associated with Hematopoietic Cell Transplantation
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell and Gene Therapy".
Deadline for manuscript submissions: 31 July 2026 | Viewed by 130
Special Issue Editors
Interests: cellular immunology; graft-versus-host disease
Interests: cellular immunology; type 1 diabetes
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Hematopoietic cell transplantation (HCT) is the only clinical option for many hematological malignancies. However, immunological complications, mainly graft-versus-host disease (GVHD), are major impediments to the clinical effectiveness of HCT. While immunosuppressive drugs have widely been used to counter such complications, the largely questionable long-term effectiveness of these agents and their toxic side effects are major hurdles. The emergence of immune cell therapy has the potential to effectively reduce the use of immunosuppressive drugs and arguably replace it altogether. Similar approaches are gaining momentum also in enhancing tolerance and improving survival of tissue grafts post-transplantation.
This Special Issue aims to collect high-quality original research articles and reviews that summarize recent novel approaches inducing tolerance and offering protection against GVHD following HCT.
Dr. Biki Gupta
Dr. Shiva Pathak
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- graft-versus-host disease
- transplantation tolerance
- immune cell therapy
- hematopoietic cell transplantation
- regulatory T cells
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
